Telios Pharmaceuticals
Executive Summary
Raises additional $5.3 mil. through private placement with European venture capitalists. Financing came from Scandinavia firm A.S. Industriforsikring and from Hambrecht & Quist Life Science Ventures, Hambrecht & Quist London, Delphi BioInvestments, Technology Funding Partners III, Ventana Growth Fund, Cabanco Fondkommission and Elf Technology. Telios has raised $22 mil. to date in addition to support received from Ono.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.